Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

At 6 months, absence of concomitant GC use (OR = 14.99; 95% CI = 1.76 to 350.19; p = 0.030; p-value [FDR] = 0.048), absence of concomitant vitamin D supplementation (OR = 21.60; 95% CI = 1.67 to 996.96; p = 0.048; p-value [FDR] = 0.048), and JAK2 rs2230722 T-allele carriage (OR = 14.08; 95% CI = 1.56 to 347.57; p = 0.039; p-value [FDR] = 0.048) were associated with higher odds of remission.

Source: 3.4.3. Multivariable Analysis. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

An ambispective observational cohort study was conducted.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Clinical and Pharmacogenetic Factors Associated with Response to JAK Inhibitors in Patients with Rheumatoid Arthritis: A Real-World Study of JAK1, JAK2, and JAK3 Gene Variants

Cohort study · Pharmaceutics · 2026

Original publication title

Clinical and Pharmacogenetic Factors Associated with Response to JAK Inhibitors in Patients with Rheumatoid Arthritis: A Real-World Study of JAK1, JAK2, and JAK3 Gene Variants

Alicia Martín Roldán; Noelia Márquez Pete; María del Mar Sánchez Suárez; Susana Rojo Tolosa; Alberto Jiménez Morales

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Background:

Janus kinase inhibitors (JAK inhibitors) have expanded therapeutic options for rheumatoid arthritis (RA), although factors associated with treatment response in routine clinical practice remain incompletely defined.

Objectives:

This study aimed to evaluate clinical, treatment-related and pharmacogenetic factors associated with response to different JAK inhibitors in patients with RA.

Methods:

An ambispective observational real-world cohort study was conducted in patients with RA treated with tofacitinib, baricitinib, filgotinib, or upadacitinib. Disease activity was assessed at 3 and 6 months using the Disease Activity Score in 28 joints based on C-reactive protein (DAS28-CRP). Clinical response was evaluated according to European Alliance of Associations for Rheumatology (EULAR) response criteria, low disease activity (LDA), and remission thresholds. Clinical, laboratory, and treatment-related variables were collected, and selected single-nucleotide polymorphisms (SNPs) in JAK1, JAK2, and JAK3 genes were genotyped. Bivariate and multivariable analyses were performed to identify variables associated with treatment outcomes.

Results:

Lower baseline inflammatory burden and lower disease activity were consistently associated with higher probabilities of EULAR response, LDA, and remission across JAK inhibitors. Treatment-related factors were also associated with improved outcomes. Pharmacogenetic associations were heterogeneous and drug-specific, with the most recurrent exploratory signals involving JAK2 variants. However, these genetic findings showed variability across outcomes and time points.

Conclusions:

In this real-world RA cohort, clinical and treatment-related factors were the most consistent variables associated with response to JAK inhibitors. Pharmacogenetic variation within the JAK pathway, particularly involving JAK2, may contribute to drug-specific variability in response, but these findings should be considered exploratory because of the limited sample size, multiple comparisons, and sparse genotype subgroups. Larger independent studies are required before JAK genotyping can be incorporated into individualized treatment strategies.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

This study aimed to evaluate clinical, treatment-related and pharmacogenetic factors associated with response to different JAK inhibitors in patients with RA.

Source: Objectives

Abstract: Results

Lower baseline inflammatory burden and lower disease activity were consistently associated with higher probabilities of EULAR response, LDA, and remission across JAK inhibitors. Treatment-related factors were also associated with improved outcomes. Pharmacogenetic associations were heterogeneous and drug-specific, with the most recurrent exploratory signals involving JAK2 variants. However, these genetic findings showed variability across outcomes and time points.

Source: Results

Abstract: Conclusions

In this real-world RA cohort, clinical and treatment-related factors were the most consistent variables associated with response to JAK inhibitors. Pharmacogenetic variation within the JAK pathway, particularly involving JAK2, may contribute to drug-specific variability in response, but these findings should be considered exploratory because of the limited sample size, multiple comparisons, and sparse genotype subgroups. Larger independent studies are required before JAK genotyping can be incorporated into individualized treatment strategies.

Source: Conclusions
Authors’ abstract

Background:

Janus kinase inhibitors (JAK inhibitors) have expanded therapeutic options for rheumatoid arthritis (RA), although factors associated with treatment response in routine clinical practice remain incompletely defined.

Objectives:

This study aimed to evaluate clinical, treatment-related and pharmacogenetic factors associated with response to different JAK inhibitors in patients with RA.

Methods:

An ambispective observational real-world cohort study was conducted in patients with RA treated with tofacitinib, baricitinib, filgotinib, or upadacitinib. Disease activity was assessed at 3 and 6 months using the Disease Activity Score in 28 joints based on C-reactive protein (DAS28-CRP). Clinical response was evaluated according to European Alliance of Associations for Rheumatology (EULAR) response criteria, low disease activity (LDA), and remission thresholds. Clinical, laboratory, and treatment-related variables were collected, and selected single-nucleotide polymorphisms (SNPs) in JAK1, JAK2, and JAK3 genes were genotyped. Bivariate and multivariable analyses were performed to identify variables associated with treatment outcomes.

Results:

Lower baseline inflammatory burden and lower disease activity were consistently associated with higher probabilities of EULAR response, LDA, and remission across JAK inhibitors. Treatment-related factors were also associated with improved outcomes. Pharmacogenetic associations were heterogeneous and drug-specific, with the most recurrent exploratory signals involving JAK2 variants. However, these genetic findings showed variability across outcomes and time points.

Conclusions:

In this real-world RA cohort, clinical and treatment-related factors were the most consistent variables associated with response to JAK inhibitors. Pharmacogenetic variation within the JAK pathway, particularly involving JAK2, may contribute to drug-specific variability in response, but these findings should be considered exploratory because of the limited sample size, multiple comparisons, and sparse genotype subgroups. Larger independent studies are required before JAK genotyping can be incorporated into individualized treatment strategies.

Publication and source details

Original title: Clinical and Pharmacogenetic Factors Associated with Response to JAK Inhibitors in Patients with Rheumatoid Arthritis: A Real-World Study of JAK1, JAK2, and JAK3 Gene Variants

Alicia Martín Roldán; Noelia Márquez Pete; María del Mar Sánchez Suárez; Susana Rojo Tolosa; Alberto Jiménez Morales

Pharmaceutics · 2026

* Correspondence: mariam.sanchez.suarez.sspa@juntadeandalucia.es (M.d.M.S.S.); susana.rojo.tolosa@juntadeandalucia.es (S.R.T.)© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Instituto de Salud Carlos IIIhttps://ror.org/00ca2c886 Hospital Universitario Virgen de las Nieveshttps://ror.org/02f01mz90 PT13/0010/0039ERDF funds (EU) from the Instituto de Salud Carlos III (PT13/0010/0039) supported by co-funding grants from the Biobank of the Hospital Universitario Virgen de las Nieves. This research did not receive any specific grant from funding agencies in the public, commercial, or non-profit sectors.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:07:55.454291+00:00

DOI: 10.3390/pharmaceutics18070846 · PMC13415438